T44.3X2 Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm

Name of the Condition

• Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm

Summary

This code describes poisoning resulting from intentional self-harm involving parasympatholytic agents, including anticholinergics, antimuscarinics, and spasmolytics. These medications reduce parasympathetic nervous system activity, affecting functions like heart rate, digestion, and muscle control. The code applies to cases where exposure is deliberate and associated with self-harm intent.

Causes

Intentional self-harm poisoning may occur due to deliberate ingestion or exposure to these agents. Common scenarios include intentional overdose, misuse of medications, or self-inflicted exposure to substances with anticholinergic properties. The cause is explicitly linked to self-harm intent.

Risk Factors

• History of mental health conditions (e.g., depression, anxiety).
• Prior episodes of self-harm or suicidal behavior.
• Access to medications with anticholinergic effects.
• Substance use disorders involving prescription or over-the-counter drugs.
• Social or environmental stressors contributing to self-harm risk.

Symptoms

• Dry mouth, blurred vision, or urinary retention.
• Confusion, dizziness, or hallucinations.
• Tachycardia or irregular heart rate.
• Gastrointestinal disturbances (e.g., nausea, constipation).
• Skin flushing or hyperthermia.
• Seizures or altered mental status.

Diagnosis

Diagnosis involves clinical evaluation of symptoms, patient history (including self-harm intent), and toxicology screening. Healthcare providers assess for anticholinergic toxidrome, which may include characteristic signs like dry mucous membranes, dilated pupils, and decreased bowel sounds. Laboratory tests and imaging may support diagnosis, particularly in severe cases.

Treatment Options

Treatment focuses on stabilizing the patient, managing symptoms, and addressing underlying self-harm intent. Interventions may include activated charcoal (if ingestion is recent), supportive care (e.g., IV fluids, monitoring of vital signs), and medications to counteract anticholinergic effects (e.g., physostigmine in severe cases). Psychiatric evaluation and follow-up are critical for addressing self-harm risk.

Prognosis and Follow-Up

Prognosis depends on the severity of poisoning, timeliness of treatment, and underlying mental health status. Mild cases may resolve with supportive care, while severe cases can lead to complications like seizures or organ damage. Follow-up includes monitoring for recurrence, psychiatric assessment, and safety planning to reduce self-harm risk.

Complications

• Seizures or status epilepticus.
• Respiratory depression or failure.
• Cardiac arrhythmias.
• Rhabdomyolysis or renal failure.
• Hyperthermia or heat stroke.
• Long-term cognitive or psychiatric effects.

Lifestyle & Prevention

• Secure storage of medications to limit access.
• Education on proper medication use and disposal.
• Mental health support and crisis intervention resources.
• Regular follow-up with healthcare providers for at-risk individuals.
• Avoidance of substance misuse or self-medication.

When to Seek Professional Help

Seek immediate medical attention if self-harm involving these medications is suspected or if symptoms like confusion, rapid heart rate, or difficulty breathing occur. Prompt care is essential to prevent severe complications. Psychiatric evaluation should be arranged to address self-harm intent and reduce future risk.

Tips for Medical Coders

Use this code for cases of intentional self-harm poisoning by parasympatholytics, anticholinergics, antimuscarinics, or spasmolytics. Document the self-harm intent clearly in the medical record. Ensure the code aligns with clinical findings and patient history, and verify that no other codes (e.g., for underlying mental health conditions) are required for complete coding.